Rheological and syringeability properties of highly concentrated human polyclonal immunoglobulin solutions

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 76, Issue 3, 2010, Pages 351-356

  Burckbuchler, V ^a,b   Mekhloufi, G ^a   Giteau, A Paillard ^b   Grossiord, J L ^a   Huille, S ^b   Agnely, F ^a  

^a UNIV PARIS SUD   (France)

^b Clinical Development   (France)

Author keywords

High concentration protein solution; Human immunoglobulin; Mooney model; Rheology; Syringeability; Viscosity

Indexed keywords

IMMUNOGLOBULIN G;

ARTICLE; FLOW KINETICS; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDRODYNAMICS; IMMUNOGLOBULIN AGGREGATE; PARTICLE SIZE; VISCOSITY;

EID: 78549239842     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2010.08.002     Document Type: Article

References (35)

1. CPMP/BPWG/388/95 TEAftEoMP, Note for guidance on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg), Rev 1.
2. Orange J.S., Hossny E.M., Weiler C.R., Ballow M., Berger M., Bonilla F.A., Buckley R., Chinen J., El-Gamal Y., Mazer B.D., Nelson R.P., Patel D.D., Secord E., Sorenson R.U., Wasserman R.L., Cunningham-Rundles C. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol. 2006, 117:S525-S553.
3. Kazatchkine M.D., Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. New Engl. J. Med. 2001, 345:747-755.
4. Chiarini F., Emmi L. The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders. Neurol. Sci. 2002, 23:S1-S8.
5. Saluja A., Kalonia D.S. Nature and consequence of protein-protein interactions in high protein concentration solutions. Int. J. Pharm. 2008, 358:1-15.
6. Shire S.J., Shahrokh Z., Liu J. Challenges in the development of high protein concentration formulations. J. Pharm. Sci. 2004, 93:1390-1402.
7. Daugherty A.L., Mrsny R.J. Formulation and delivery issues for monoclonal antibody therapeutics. Adv. Drug Deliv. Rev. 2006, 58:686-706.
8. Wang W., Singh S., Zeng D.L., King K., Nema S. Antibody structure instability and formulation. J. Pharm. Sci. 2007, 96:1-26.
9. Cleland J. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit. Rev. Ther. Drug Carrier Syst. 1994, 11:60.
10. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol. Dial Transplant. 2005, 20:vi3-vi9.
11. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther. 2002, 24:1720-1740.
12. Ahrer K., Buchacher A., Iberer G., Jungbauer A. Effects of ultra-/diafiltration conditions on present aggregates in human IgG preparations. J. Membr. Sci. 2006, 247:108-115.
13. Szenczi A., Kardos J., Medgyesi G.A., Zavodsky P. The effect of solvent environment on the conformation and stability of human IgG in solution. Biologicals 2006, 34:5-14.
14. Wang W., Nema S., Teagarden D. Protein-aggregation - pathways and influencing factors. Int. J. Pharm. 2010, 390:89-99.
15. Einstein A. Eine neue bestimmung der moleküldimensionen. Ann. Phys. 1906, 19:289-306.
16. Einstein A. A new determination of molecular dimensions. Investigations on the Theory of the Brownian Movement 1956, Dover, New York. R. Fürth (Ed.).
17. Mooney M. The viscosity of a concentrated suspension of spherical particles. J. Colloid Sci. 1951, 6:162-170.
18. Pal R. Rheology of blends of suspensions and emulsions. Ind. Eng. Chem. Res. 1999, 38:5005-5010.
19. Zhou Z., Scales P.J., Boger D.V. Chemical and physical control of the rheology of concentrated metal oxide suspensions. Chem. Eng. Sci. 2001, 56:2901-2920.
20. Choi H.J., Kim C.A., Kwon T.M., Jhon M.S. Viscosity of magnetic particle suspensions. J. Magn. Magn. Mater. 2000, 209:228-230.
21. Monkos K., Turczynski B. A comparative study on viscosity of human, bovine and pig IgG immunoglobulins in aqueous solutions. Int. J. Biol. Marcomol. 1999, 26:155-159.
22. McClain B.L., Finkelstein I.J., Fayer M.D. Dynamics of hemoglobin in human erythrocytes and in solution: influence of viscosity studied by ultrafast vibrational echo experiments. J. Am. Chem. Soc. 2004, 126:15702-15710.
23. Liu J., Nguyen M.D.H., Andya J.D., Shire S.J. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J. Pharm. Sci. 2005, 94:1928-1940.
24. Saluja A., Badkar A.V., Zeng D.L., Nema S., Kalonia D.S. Application of high frequency rheology measurements for analyzing protein-protein interactions in high protein concentration solutions using a model monoclonal antibody (IgG2). J. Pharm. Sci. 2006, 95:1967-1983.
25. Kanai S., Liu J., Patapoff T.W., Shire S.J. Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab interaction that impacts solution viscosity. J. Pharm. Sci. 2008, 97:4219-4227.
26. Cohn E., Strong L., Hughes W., Mulford D., Ashworth J., Melin M., Taylor H.L. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluid. J. Am. Chem. Soc. 1946, 68:459-475.
27. Flan B. Fractionation technique and biochemical properties of IV Ig. Sang Thromb. Vaiss. 1999, 11:45S-51S.
28. Ahrer K., Buchacher A., Iberer G., Jungbauer A. Detection of aggregate formation during production of human immunoglobulin G by means of light scattering. J. Chromatogr. A 2004, 1043:41-46.
29. Macosko C.W. Viscous liquid. Rheology. Principles, Measurements, and Applications 1994, Wiley-VCH. C.W. Macosko (Ed.).
30. Kamerzell T.M., Kanai S., Liu J., Shire S.J., Wang J. Increasing IgG concentration modulates the conformational heterogeneity and bonding network that influence solution properties. J. Phys. Chem. B 2009, 113:6109-6118.
31. S. Yadav, S.J. Shire, D.S. Kalonia, Factors affecting the viscosity in high concentration solutions of different monoclonal antibodies, J. Pharm. Sci., in press, Available online: 28 June 2010, doi:10.1002/jps.22190.
32. Yadav S., Liu J., Shire S.J., Kalonia D.S. Specific interactions in high concentration antibody solutions resulting in high viscosity. J. Pharm. Sci. 2009, 99:1152-1168.
33. Werner T.C., Bunting J.R., Cathou R.E. The shape of immunoglobulin G molecules in solution. Proc. Natl. Acad. Sci. 1972, 69:795-799.
34. Kuhn W., Kuhn H. Die Abhängigkeit der Viskosität vom Strömungsgefälle bei hochverdünnten Suspensionen und Lösungen. Helv. Chim. Acta 1945, 28:97.
35. Monkos K. Concentration and temperature dependence of viscosity in lysozyme aqueous solutions. Biochim. Biophys. Acta 1997, 1339:304-310.